Re: SABCS denosumab increases disease-free survival & reduces fractures 50% for er+s,
I asked for this instead of zometa but told I don't fit UK criteria (too young, no kidney problems) & expensive. Think the main reason is expense! Really disappointed as I have read that it is superior.
Have also read that it can cause a rash with xeloda so maybe would still be excluded anyway.
|